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tiswellknownthatadipocytesandres-
ident macrophages that have migrated
to adipose tissue produce and secrete a
variety of biologically active mediators
(adipocytokines), which are thought to
contribute to the development of insulin
resistance,type2diabetes,andcardiovas-
cular disease (1).
The abnormal function of adipocytes
may play an important role in the devel-
opment of a chronic low-grade proin-
ﬂammatory state associated with obesity
(2). For example, adipocyte hypertrophy
appears to lead to an imbalance between
pro- and anti-inﬂammatory adipokines.
The secretion of interleukin (IL)-6, IL-8,
monocyte chemoattractant protein-1,
and granulocyte colony–stimulating fac-
tor have been positively correlated with
adipocyte size.
Adiposetissueisanimportantinﬂam-
matory source in obesity and type 2 dia-
betes, not only because of cytokines
produced from the adipocyte itself, but
also because of inﬁltration by proinﬂam-
matory macrophages (3). Not only do
adipocytes, but also adipose tissue mac-
rophage numbers, increase with obesity
andparticipateininﬂammatorypathways
of obese individuals. Macrophages from
adipose tissue are responsible for almost
all adipose tissue tumor necrosis factor
(TNF)- and signiﬁcant amounts of IL-6
production. Macrophages migrating to
adipose tissue in response to high-fat
feeding overexpress proinﬂammatory
cytokines.
Different cytokines synthesized by
adipocytes or by macrophages from adi-
pose tissue may induce insulin resistance,
such as IL-6, TNF-, leptin, resistin, adi-
ponectin, retinol binding protein-4
(RBP4), or lipocalin-2 (LCN2). This re-
viewfocusesonthelatteradipocytokines,
hinting at their role in obesity-associated
insulin resistance.
LCN2— LCN2 (or neutrophil gelati-
nase-associated lipocalin) is a recently
identiﬁed adipokine that belongs to the
superfamily of lipocalins (such as RBP4),
which seems to affect glucose metabolism
and insulin sensitivity (4). LCN2 protein
has been implicated in diverse actions,
such as apoptosis and innate immunity,
andisexpressedinseveraltissues,includ-
ingneutrophils,liver,kidney,adipocytes,
and macrophages (5).
Lipocalins comprise a class of pro-
teins that are characterized by eight B-
strands that form a B-barrel deﬁning a
calyx. The calyx binds and transports a
wide variety of molecules, such as retinol,
fatty acids, and steroids, which are
thought to deﬁne the biologic activity of
the lipocalin.
LCN2 deﬁciency in mice resulted in
an increased susceptibility to bacterial in-
fection (6). Lipopolysaccharide and
TNF- are two of the strongest inducers
of LCN2 production. Recently, the LCN2
gene was also identiﬁed as a novel IL-17–
induced gene (7).
LCN2 is highly expressed in adipose
tissue in vivo and in vitro, and its secre-
tion is regulated by the activation of in-
ﬂammation and infection (4). LCN2
mRNA is also elevated in the liver of ob/ob
mice, and circulating LCN2 levels are in-
creased in obese animals and human sub-
jects with type 2 diabetes (5,8). In fact,
expression of LCN2 is elevated by agents
that promote insulin resistance and is re-
duced by thiazolidinediones (8). In one
study, serum concentrations of LCN2
were positively associated with waist cir-
cumference, percent body fat, systolic
blood pressure, fasting glucose and insu-
lin concentrations, fasting triglycerides,
and markers for chronic inﬂammation.
All these results persisted signiﬁcantly af-
ter adjustment for sex and age (5). In an-
other study, serum LCN2 levels were
signiﬁcantlyelevatedinpatientswithcor-
onary heart disease and were indepen-
dentlyassociatedwithatherosclerosis(9).
Information on the dual effects of
LCN2 on inﬂammation is sparse. The
LCN2 promoter contains different bind-
ing sites for two proinﬂammatory tran-
scription factors: nuclear factor kB (NF-
B) and CCAAT/enhancer-binding
protein (C/EBP) (7). Expression of LCN2
waselevatedbyagentsthatpromoteinsu-
lin resistance and was reduced by thiazo-
lidinediones (8), partially explaining why
activation of this gene in adipose tissue
was associated with inﬂammation and
obesity. Paradoxically, decreased LCN2
gene expression has no signiﬁcant effect
on lipid accumulation in adipocytes (8).
Conversely, LCN2 has recently been
claimed to display anti-inﬂammatory ef-
fects, so that increased LCN2 levels in
obesity and insulin resistance may con-
stitute a protective mechanism against
inﬂammation (10). Moreover, LCN2
upregulated peroxisome proliferator–
activated receptor (PPAR)- and its target
genes, adiponectin, leptin, fatty acid syn-
thase, and lipoprotein lipase in adipo-
cytes. Concurrently, LCN2 antagonized
TNF- effects on adipocytes and macro-
phages: LCN2 protected adipocytes from
TNF-–induced production of IL-6 and
monocyte chemoattractant protein-1
(MCP-1),attenuatedTNF-effectonglu-
cose uptake, and completely reversed
TNF- inhibition of leptin and adiponec-
tin secretion from adipocytes. The stimu-
latory effect of lipopolysaccharide on
cytokine gene expression in macrophages
wasalsosigniﬁcantlyattenuatedbyLCN2
(10). Knocking down LCN2 expression
resulted in decreased expression of
PPAR-. This suggests an anti-inﬂamma-
tory effect of LCN2, via direct or indirect
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NFB activity (10).
An additional mechanism that links
LCN2toinﬂammationisprobablyrelated
to its structural characteristics, which al-
low the binding and transport of other
molecules. LCN2 may take part in the
host innate immune defense system. In
fact, bacteriostatic effects are exerted by
LCN2, and these effects are mediated
through the binding of bacterial enter-
obactin siderophores to limit bacterial
iron acquisition.
In conclusion, although LCN2 is di-
rectly linked to inﬂammation in associa-
tion studies, the speciﬁc role of this
molecule should be clariﬁed. The in-
creased levels of LCN2 during inﬂamma-
tion may reﬂect a protective role against
inﬂammation.
RBP4— RBP4 is a molecule found in
the circulation, thought to be secreted
mainly by adipose tissue and the liver
(11). In the circulation, RBP4 is the prin-
cipal transport protein for retinol (vita-
min A) (11) and is encoded by the RBP4
gene, localized in the chromosome
10q23-q24 (12).
Increased serum RBP4 levels have
beenreportedinsubjectswithobesity,in-
sulin resistance, and type 2 diabetes (13)
and in other insulin-resistant states, such
as nonalcoholic fatty liver disease and the
metabolic syndrome. Serum RBP4 con-
centration was negatively associated with
insulin sensitivity measured by the clamp
and was associated with type 2 diabetes
development (13,14). However, these as-
sociations were not found by other inves-
tigators (15,16).
Circulating RBP4 concentration cor-
relatedpositivelywithadipositymeasures
and with inﬂammatory parameters. Cir-
culatingRBP4concentrationwasmoreas-
sociated with waist circumference and
percent trunk fat than with percent body
fat (17). The association between RBP4
and visceral fat was stronger than its asso-
ciation with BMI, indicating a greater role
of visceral than subcutaneous fat in the
relationship between RBP4 and insulin
resistance. This ﬁnding was conﬁrmed by
other authors who described that visceral
adipose tissue accumulation was the
stronger predictor of RBP4 levels (18). In
this sense, increased RBP4 mRNA expres-
sion in visceral, compared with subcuta-
neous, adipose tissue has already been
found (19). Circulating RBP4 levels also
correlated positively with ectopic fat ac-
cumulation at hepatic and skeletal mus-
cles (14).
TheRBP4geneticvariationswerealso
likely to affect measures of insulin resis-
tance, BMI, waist-to-hip ratio, and circu-
lating free fatty acids. Recent data
indicatedaroleforRBP4geneticvariation
in susceptibility to type 2 diabetes and
insulin resistance, possibly through an ef-
fect on RBP4 expression. The RBP4 hap-
lotypes were related to an increased risk
of type 2 diabetes (12,20). Diabetes risk
RBP4 haplotype carriers had a higher
mean visceral and subcutaneous RBP4
mRNA expression, compared with non-
carriers (12). However, the associations
among RBP4 levels, RBP4 gene expres-
sion, and measures of obesity or insulin
resistance have not been universally de-
scribed (15).
Several mechanisms link RBP4 to in-
sulin resistance and type 2 diabetes.
Transgenic expression of RBP4 in mice
caused insulin resistance, whereas exper-
imentally decreased RBP4 levels amelio-
rated insulin resistance. Other RBP4-
Figure 1—Brief summary of the adipocytokines discussed: increased adipose tissue mass is associated with decreased adiponectin levels and
increased RBP4, IL-6, and TNF- production, which in turn stimulates LCN2 synthesis. LCN2 upregulates adiponectin and downregulates TNF-.
Decreased adiponectin and increased RBP4 levels are associated with decreased fatty acid oxidation, increased gluconeogenesis in the liver, and
insulin resistance. FFA, free fatty acid; ICAM-1, intercellular adhesion molecule-1; IR, insulin receptor; IRS, insulin receptor substrate; PPAR,
peroxisome proliferator-activated receptor; SR-A, scavenger receptor-A; VCAM-1, vascular cell adhesion molecule-1.
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hepatic gluconeogenesis by enhancing
the expression of phosphoenolpyruvate
carboxykinase in the liver and the atten-
uated insulin signaling in skeletal muscle
(11). Insulin signaling in primary human
adipocytes was affected by RBP4 through
blocking the insulin-stimulated phos-
phorylation of insulin receptor sub-
strate-1atserineinposition307(21).The
level of GLUT4 protein in human adipo-
cytes correlated positively with the rate of
glucose disposal and inversely with the
serum RBP4 level (13).
The link between RBP4 and type 2
diabetes could also be mediated through
impaired insulin secretion. In one study,
circulating RBP4 concentration was neg-
ativelyassociatedwithinsulinsecretionin
humans. In fact, it is well known that ret-
inol (the ligand for RBP4) is pathophysi-
ologically linked to -cell function.
Retinol-binding protein circulates in se-
rum, forming a complex with transthyre-
tin, a transport protein for thyroxine. A
recent investigation disclosed that transt-
hyretin constitutes a functional compo-
nent in pancreatic -cell stimulus-
secretioncoupling.ThebindingofRBPto
the receptor is inhibited by transthyretin.
Thus, it is possible that increased serum
RBP4 prevents transthyretin from exert-
ing its -cell stimulus-secretion effects
(16).
However, the mechanisms by which
RBP4 induces insulin resistance are not
well understood. Many adipokines have
been found to be sexually dimorphic.
Both leptin and adiponectin are increased
in serum of women compared with men.
This observation has been explained on
thebasisofdifferentfatquantitiesandthe
inﬂuence of sex hormones. Plasma RBP4
concentrations, however, exhibit an op-
posite pattern. The median (range) for
RBP4inplasmawashigherinmenthanin
women (22). Plasma RBP4 levels in
women over the age of 50 years were
found to be signiﬁcantly higher than
thoseinwomenundertheageof50years.
No such age-associated difference in RBP4
plasma levels was observed in men (22).
Thus,thepatternofRBP4concentrationsin
serum resembles that of iron stores: higher
in men than women, in whom iron stores
increase after menopause.
An interaction between iron and vita-
min A status, of which RBP4 is a surro-
gate, has long been recognized. For
instance,vitaminAdeﬁciencymayimpair
iron metabolism and aggravate anemia,
and iron deﬁciency anemia and vitamin A
deﬁciency often coexist. Iron supplemen-
tation signiﬁcantly increased plasma reti-
nol and RBP (23).
In recent years, increased iron intake
and raised iron stores have been recog-
nized as signiﬁcant independent contrib-
utors to insulin resistance. Interestingly,
serum ferritin concentration was posi-
tively associated with serum RBP4 con-
centration in two independent samples
(23). On multiple regression analyses to
predict serum RBP4, log serum ferritin
contributed signiﬁcantly to RBP4 vari-
ance after controlling for BMI, age, and
homeostasis model assessment value.
Furthermore, serum RBP4 concentration
decreased after iron depletion in type 2
diabetic patients. Finally, the iron donor,
lactoferrin, led to increased dose-
dependent adipose tissue release of RBP4
(2.4-fold) and increased RBP4 expression,
whereas apotransferrin and deferoxamine
led to decreased RBP4 release (23).
Signiﬁcant weight loss induced by
diet, lifestyle interventions, bariatric sur-
gery (gastric bypass), and gastric banding
surgery led to decreased circulating RBP4
levels (24). The decrease in RBP4 in re-
sponse to the intervention was closely as-
sociated to the decrease of inﬂammatory
factors (C-reactive protein and IL-6).
Nevertheless, smaller decreases in body
weight after dietetic intervention did not
induce the same effects on RBP4 levels.
Improved insulin resistance by exer-
cise also reduced RBP4 levels and in-
creased circulating adiponectin (13).
Therefore, the insulin-sensitizing effects
of exercise are associated with decreased
RBP4.
Insummary,therearereliableclinical
and research studies suggesting the asso-
ciation of RBP4 with obesity and insulin
resistance.
ADIPONECTIN— Adiponectin, be-
lieved to be produced almost exclusively
by mature adipocytes, is the prototype of
anti-inﬂammatory adipocytokines, de-
creased in obesity, and inversely corre-
lated with insulin resistance, glucose
intolerance, dyslipidemia, and athero-
sclerosis. Adiponectin receptors (Adi-
poR)-1 and -2 are expressed in peripheral
tissues and in the brain, where adiponec-
tin mediates fatty acid metabolism and
modulates energy homeostasis (25).
Adiponectin production is well
known to be regulated by different cyto-
kines. Adiponectin gene expression is
known to be reduced by TNF- and IL-6,
whereas insulin sensitizers and PPAR-
agonists have been shown to increase adi-
ponectin levels in mice and humans (25).
The negative relationship between
adiponectinandadiposetissueisstronger
withvisceralfatratherthansubcutaneous
fat.Forinstance,obeseadolescentswitha
high proportion of visceral fat and rela-
tively low abdominal subcutaneous fat
have decreased adiponectin and leptin
levels independent of body weight (26).
The reason why visceral adipocytes pro-
duce more adiponectin than adipocytes
isolated from subcutaneous fat is rather
puzzling.
In intervention studies, circulating
adiponectin levels increased after weight
loss in humans. Diet, gastric bypass sur-
gery, orlistat, or selective CB1-receptor
blockade with rimonabant signiﬁcantly
increased adiponectin levels in parallel to
reduced body weight (27). Thiazo-
lidinediones increased adiponectin ex-
pression and circulating levels in rodents,
nondiabetic subjects, and patients with
type2diabetes(28).Exercisewithoutsig-
niﬁcantweightlossdidnotaffectcirculat-
ing adiponectin, but improved insulin
resistance, suggesting different pathways
fortheinsulin-sensitivemechanismofex-
ercise other than adipokine modulation
(28).
Genetic polymorphisms, sex, and di-
etaryfactors,suchassoyprotein,ﬁshoils,
linoleic acid, and carbohydrate-rich diets
also inﬂuence circulating adiponectin
(28).
Adiponectin and insulin sensitivity
Circulating adiponectin levels are posi-
tively correlated with insulin sensitivity
evaluated by using different insulin sensi-
tivity techniques (28). Adiponectin gene
expression and circulating adiponectin
levels are lower in patients with type 2
diabetes than in nondiabetic individuals
(28).Inaprospectivestudyof3,599non-
diabetic men followed up for 5 years, low
adiponectin was associated with in-
creased risk of type 2 diabetes, even after
adjustment for traditional risk factors,
and the same results were found in a co-
hort study representing the 9-year ex-
perience of the 10,275 middle-aged U.S.
African American and Caucasian partici-
pants of the Atherosclerosis Risk in Com-
munities Study and in the Hoorn Study
(29,30).
Several single-nucleotide polymor-
phisms and mutations in the adiponectin
gene have been reported to be linked to
type2diabetesandhypoadiponectinemia
in different ethnic groups (25).
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Adiponectin-deﬁcient mice develop insu-
lin resistance, glucose intolerance, in-
creased lipid deposition in muscle,
hyperlipidemia, and increased suscepti-
bilitytoatherosclerosis(28).Adiponectin
administration led to decreased circulat-
ing glucose levels in both normal mice
and mouse models of diabetes (25). Mice
overexpressing adiponectin showed nor-
malized glucose and partial amelioration
of insulin resistance and diabetes and a
reduction in macrophage inﬁltration in
adipose tissue and systemic inﬂammation
(31).
Adiponectin plays a special role in
insulin sensitivity in the liver. Adi-
ponectin lowers hepatic gluconeogene-
sis in mice (25), enhances the effects of
insulin to decrease glucose production
by isolated hepatocytes, and decreases
hepatic triglyceride deposition (25).
Moreover, adiponectin can also reduce
ectopic fat deposition in muscle via in-
creases of fat oxidation (28), improving
insulin signal transduction. Accord-
ingly, low adiponectin concentrations
in obese adolescent subjects are associ-
ated with increased intramyocellular
lipid deposition and impaired insulin
action (32).
Molecular mechanisms
Adiponectin exerts its effects on energy
homeostasis, and glucose and lipid me-
tabolism through phosphorylation and
activation of adenosine monophosphate-
activated protein kinase (AMPK) (25).
The AMPK activation stimulates phos-
phorylation of acetyl CoA carboxylase,
fattyacidoxidationandglucoseuptakein
myocytes, and reduces enzymes involved
in gluconeogenesis in liver, leading to re-
duction of glucose levels (25).
Adiponectin also increased the ex-
pressionlevelsofPPAR-invivo,increas-
ing fatty acid combustion and energy
consumption, which led to decreased tri-
glyceride content in the liver and skeletal
muscle, and thus increased insulin sensi-
tivity. Moreover, PPAR- activation pre-
vented inﬂammation in adipose tissue
and enhanced the action of adiponectin
by increasing both adiponectin and adi-
ponectin receptors, which can result in
the amelioration of obesity-induced insu-
lin resistance (28,31).
Adiponectin and atherosclerosis
Studies in animal models and humans
have shown associations among adi-
ponectin, endothelial function, and car-
diovascular disease (33). Adiponectin has
been reported to have direct anti-
atherosclerotic effects by suppressing the
expression of intracellular adhesion mol-
ecule-1, E-selectin, and vascular cellular
adhesion molecule-1, as well as by reduc-
ing the effects of TNF-mediated proin-
ﬂammatory changes on endothelial cells.
Adiponectininhibitstheexpressionofthe
macrophage-associated scavenger recep-
tor class A-1, decreasing foam cell forma-
tion (25). Globular adiponectin also
inhibits oxidized LDL–mediated endo-
thelial proliferation and formation of re-
active oxygen species integral to vascular
damage. Adiponectin knockout mice de-
veloped severe vascular alterations, in-
cluding reduced vasodilation in response
to acetylcholine, neointimal thickening,
and increased proliferation of smooth
muscle cells in arteries after injury, while
overexpression of adiponectin in mice re-
sulted in marked reduction of atheroscle-
rotic lesion formation (25).
In addition to the direct protective ef-
fects of adiponectin on vascular endothe-
lium, the associations between low
adiponectin and atherosclerosis are in
partduetoitsrelationshipwithothercar-
diovascular risk factors, such as insulin
resistance, type 2 diabetes, intra-
abdominal body fat distribution, hyper-
tension, small dense LDL, triglycerides,
and HDL levels (34).
Although the anti-atherosclerotic ef-
fectsofadiponectinseemtobestrong,the
association between adiponectin and car-
diovascular disease risk in different pro-
spective and case-control studies is
comparatively moderate or not signiﬁ-
cant, especially after adjusting for HDL
cholesterol levels (35).
Recent controversies
Despite the well-known insulin-
sensitizingandanti-atheroscleroticeffects
of adiponectin, recent ﬁndings disclosed
unsuspected relationships. In a cohort of
male patients with high cardiovascular
risk, plasma adiponectin was indepen-
dentlypredictiveofthesubsequentriskof
death and myocardial infarction (36).
High adiponectin levels were also found
as predictors of mortality in subjects with
chronic heart failure (37). Simvastatin
treatment improved endothelium-
dependent vasodilation but reduced adi-
ponectin levels (38). The contradictory
ﬁndings can be explained in part by the
stratiﬁcation of different cardiovascular
risk factors in the populations studied. As
previously suggested, increased secretion
of adiponectin may reﬂect an insufﬁcient
response to avoid endothelial damage in
subjects with high cardiovascular risk.
However, in other high-risk populations,
this hypothesis could not be conﬁrmed
(36).
Despite the well-documented nega-
tive association between adiponectin and
several inﬂammatory factors, adiponectin
was found to be actually increased in
chronic inﬂammation associated with au-
toimmune diseases, such as type 1 diabe-
tes, systemic lupus erythematosus,
rheumatoid arthritis, and inﬂammatory
bowel disease, suggesting that adiponec-
tin increases in chronic inﬂammation not
associated with obesity. It is possible that
adiponectin could have a protective role
intheinﬂammationrelatedtoadiposetis-
sue loss during starvation and fasting, but
not in inﬂammation unassociated with
obesity.
CONCLUSIONS — Genetic predis-
position, overt and inappropriate nutrition,
and different environmental inﬂuences
lead to obesity or hyperplasia of adipose
tissue and to inﬁltration by proinﬂamma-
tory macrophages. Increased adipose tis-
sue produces and secretes a variety of
biologically active mediators (adipocyto-
kines) that are thought to contribute to
the development of insulin resistance,
type 2 diabetes, and cardiovascular dis-
ease. Inﬂammatory factors, such as IL-6,
TNF-, and RBP4, can induce insulin re-
sistance by antagonizing insulin action at
peripheral tissues, especially the liver and
skeletal muscle. Several other adipokines
produced by the adipocytes, including
adiponectin (and possibly LCN2), dem-
onstrated insulin-sensitizing activity and
cardiovascular protection.
Despite the well-characterized pro-
tective effects of adiponectin on insulin
resistance and atherosclerosis, the diver-
gent ﬁndings concerning the role of adi-
ponectin on chronic inﬂammation not
associated with obesity should be con-
ﬁrmed. The direct anti-atherosclerotic ef-
fects of adiponectin without the inﬂuence
of insulin resistance and dyslipidemia
should also be clariﬁed. More data on the
role of LCN2 on inﬂammation in humans
are needed. The in vivo balances of differ-
ent pro- and anti-inﬂammatory cytokines
and their diverging interrelationships
need to be explored in depth to under-
stand the different biological pathways
that are involved (Fig. 1).
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